Drugs / UTAA09
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06417398 | May → Dec 2024 | Sjogren syndrome, autoimmune thrombocytopenia, idiopathic inflammatory myopathy, primary biliary cholangitis +3 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT06092047 | Oct 2023 → Jul 2026 overdue | B-cell neoplasm | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06361745 | Apr → Dec 2024 | Sjogren syndrome, idiopathic inflammatory myopathy, immunoglobulin G4-related sclerosing disease, systemic lupus erythematosus +1 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UTAA09 | “dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection)” NCT06361745 ↗ |
| Known as | CD19-CAR-gdT | “dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection)” NCT06361745 ↗1“CD19-CAR-gdT (UTAA09 injection)” NCT06417398 ↗ |
| Known as | UTAA09 injection | “after administration of UTAA09 injection in patients with CD19-positive relapsed/refractory B-cell hematolymphatic malignancies” NCT06092047 ↗ |
| Modality | Cell therapy | “recombinant allogeneic healthy γδT cells transduced with the anti-CD19 lentiviral vector” NCT06092047 ↗ |
| Route | Intravenous | “Route of administration: Intravenous injection” NCT06092047 ↗ |
| Target | CD19 | “Off-the-shelf γδT cells with a CD19-redirected Chimeric Antigen Receptor” NCT06092047 ↗ |